Current  ||| S:0 E:8 ||| JJ
indications  ||| S:8 E:20 ||| NNS
for  ||| S:20 E:24 ||| IN
prevention  ||| S:24 E:35 ||| NN
and  ||| S:35 E:39 ||| CC
therapy  ||| S:39 E:47 ||| NN
of  ||| S:47 E:50 ||| IN
steroid-induced  ||| S:50 E:66 ||| JJ
osteoporosis  ||| S:66 E:79 ||| NN
in  ||| S:79 E:82 ||| IN
men  ||| S:82 E:86 ||| NNS
and  ||| S:86 E:90 ||| CC
women  ||| S:90 E:96 ||| NNS
Steroid-induced  ||| S:96 E:112 ||| JJ
osteoporosis  ||| S:112 E:125 ||| NN
is  ||| S:125 E:128 ||| VBZ
a  ||| S:128 E:130 ||| DT
textbook  ||| S:130 E:139 ||| JJ
example  ||| S:139 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
the  ||| S:150 E:154 ||| DT
secondary  ||| S:154 E:164 ||| JJ
type  ||| S:164 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
this  ||| S:172 E:177 ||| DT
medical  ||| S:177 E:185 ||| JJ
condition ||| S:185 E:194 ||| NN
.  ||| S:194 E:196 ||| .
Glucocorticosteroids  ||| S:196 E:217 ||| JJ
suppress  ||| S:217 E:226 ||| JJ
bone  ||| S:226 E:231 ||| NN
formation  ||| S:231 E:241 ||| NN
by  ||| S:241 E:244 ||| IN
their  ||| S:244 E:250 ||| PRP$
direct  ||| S:250 E:257 ||| JJ
and  ||| S:257 E:261 ||| CC
indirect  ||| S:261 E:270 ||| JJ
effect  ||| S:270 E:277 ||| NN
on  ||| S:277 E:280 ||| IN
osteoblasts ||| S:280 E:291 ||| NN
,  ||| S:291 E:293 ||| ,
osteoclasts  ||| S:293 E:305 ||| NN
and  ||| S:305 E:309 ||| CC
osteocytes ||| S:309 E:319 ||| NN
,  ||| S:319 E:321 ||| ,
increasing  ||| S:321 E:332 ||| VBG
their  ||| S:332 E:338 ||| PRP$
resorption  ||| S:338 E:349 ||| NN
and ||| S:349 E:352 ||| CC
,  ||| S:352 E:354 ||| ,
eventually ||| S:354 E:364 ||| RB
,  ||| S:364 E:366 ||| ,
leading  ||| S:366 E:374 ||| VBG
to  ||| S:374 E:377 ||| TO
negative  ||| S:377 E:386 ||| JJ
bone  ||| S:386 E:391 ||| NN
balance ||| S:391 E:398 ||| NN
.  ||| S:398 E:400 ||| .
A  ||| S:400 E:402 ||| DT
clinical  ||| S:402 E:411 ||| JJ
problem  ||| S:411 E:419 ||| NN
arises  ||| S:419 E:426 ||| VBZ
regarding  ||| S:426 E:436 ||| VBG
the  ||| S:436 E:440 ||| DT
fact  ||| S:440 E:445 ||| NN
that  ||| S:445 E:450 ||| WDT
approximately  ||| S:450 E:464 ||| RB
50 ||| S:464 E:466 ||| CD
%  ||| S:466 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
patients  ||| S:471 E:480 ||| NNS
on  ||| S:480 E:483 ||| IN
chronic  ||| S:483 E:491 ||| FW
steroid  ||| S:491 E:499 ||| FW
therapy  ||| S:499 E:507 ||| FW
undergo  ||| S:507 E:515 ||| FW
asymptomatic  ||| S:515 E:528 ||| FW
bone  ||| S:528 E:533 ||| FW
fractures ||| S:533 E:542 ||| FW
.  ||| S:542 E:544 ||| .
The  ||| S:544 E:548 ||| DT
treatment  ||| S:548 E:558 ||| NN
mode  ||| S:558 E:563 ||| NN
includes  ||| S:563 E:572 ||| VBZ
minimising  ||| S:572 E:583 ||| VBG
the  ||| S:583 E:587 ||| DT
dose  ||| S:587 E:592 ||| NN
of  ||| S:592 E:595 ||| IN
administered  ||| S:595 E:608 ||| JJ
steroids ||| S:608 E:616 ||| NNS
,  ||| S:616 E:618 ||| ,
encouraging  ||| S:618 E:630 ||| VBG
an  ||| S:630 E:633 ||| DT
improved  ||| S:633 E:642 ||| JJ
lifestyle  ||| S:642 E:652 ||| NN
and  ||| S:652 E:656 ||| CC
supplementation  ||| S:656 E:672 ||| NN
with  ||| S:672 E:677 ||| IN
adequate  ||| S:677 E:686 ||| JJ
calcium  ||| S:686 E:694 ||| NN
and  ||| S:694 E:698 ||| CC
vitamin  ||| S:698 E:706 ||| JJ
D ||| S:706 E:707 ||| NNP
( ||| S:707 E:708 ||| -LRB-
3 ||| S:708 E:709 ||| LS
)  ||| S:709 E:711 ||| -RRB-
doses ||| S:711 E:716 ||| NNS
.  ||| S:716 E:718 ||| .
Bisphosphonates  ||| S:718 E:734 ||| NNS
are  ||| S:734 E:738 ||| VBP
a  ||| S:738 E:740 ||| DT
group  ||| S:740 E:746 ||| NN
of  ||| S:746 E:749 ||| IN
medical  ||| S:749 E:757 ||| JJ
agents  ||| S:757 E:764 ||| NNS
used  ||| S:764 E:769 ||| VBD
both  ||| S:769 E:774 ||| DT
to  ||| S:774 E:777 ||| TO
prevent  ||| S:777 E:785 ||| VB
and  ||| S:785 E:789 ||| CC
treat  ||| S:789 E:795 ||| VB
steroid-induced  ||| S:795 E:811 ||| JJ
osteoporosis ||| S:811 E:823 ||| NN
,  ||| S:823 E:825 ||| ,
although  ||| S:825 E:834 ||| IN
new  ||| S:834 E:838 ||| JJ
therapies  ||| S:838 E:848 ||| NNS
have  ||| S:848 E:853 ||| VBP
also  ||| S:853 E:858 ||| RB
become  ||| S:858 E:865 ||| VB
available  ||| S:865 E:875 ||| JJ
in  ||| S:875 E:878 ||| IN
recent  ||| S:878 E:885 ||| JJ
years ||| S:885 E:890 ||| NNS
.  ||| S:890 E:892 ||| .
